CG

Neurobiologic Theories and Psychopharmacology

Central Nervous System

  • Brain

    • consists of the cerebrum, cerebellum, brain stem, and limbic system

  • Cerebrum

    • divided into two hemispheres

      • cerebral hemispheres are divided into four lobes:

        • frontal

          • control the organization of thought, body movement, memories, emotions, and moral behavior

          • abnormalities are associated with schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and

            dementia

        • parietal

          • interpret sensations of taste and touch and assist in spatial orientation

        • temporal

          • centers for the senses of smell and hearing and for memory and emotional expression

        • occipital

          • assist in coordinating language generation and visual interpretation, such as depth perception

    • all lobes and structures are found in both halves except for the pineal body, or gland, which is located between the hemispheres

  • Cerebellum

  • Brain Stem

  • Limbic System

    • area of the brain located above the brain stem and consists of:

      • thalamus

        • regulates activity, sensation, and emotion

      • hypothalamus

        • involved in temperature regulation, appetite control, endocrine function, sexual drive, and impulsive behavior associated with feelings of anger, rage, or excitement.

      • hippocampus and amygdala

        • involved in emotional arousal and memory

    • Disturbances in the limbic system have been implicated in a variety of mental illnesses:

      • memory loss that accompanies dementia

      • poorly controlled emotions and impulses seen with psychotic or manic behavior

Neurotransmitters

  • the chemical substances manufactured in the neuron that aid in the transmission of information throughout the body

  • either:

    • Excitatory - excite or stimulate an action in the cells

    • Inhibitory - inhibit or stop an action

  • fit into specific receptor cells embedded in the membrane of the dendrite

  • after being released either:

    • Reuptake - transported back from the synapse to the axon to be stored for later use

    • Metabolized and inactivated by enzymes, primarily monoamine oxidase (MAO)

Major Nuerotransmitters

  • Dopamine

    • Excitatory

    • Controls complex movements, motivation, cognition; regulates emotional response

  • Norepinephrine (noradrenaline)

    • Excitatory

    • Causes changes in attention, learning and memory, sleep and wakefulness, moods

  • Epinephrine (adrenaline)

    • Excitatory

    • Controls fight or flight response

  • Serotonin

    • Inhibitory

    • Controls food intake, sleep and wakefulness, temperature regulation, pain control, sexual behaviors, regulation of emotions

  • Histamine

    • Neuromodulator

    • Controls alertness, gastric secretions, cardiac stimulation, peripheral allergic responses

  • Acetylcholine

    • Excitatory or inhibitory

    • Controls sleep and wakefulness cycle; signals muscles to become alert

  • Neuropeptides

    • Neuromodulators

    • Enhance, prolong, inhibit, or limit the effects of principal neurotransmitters

  • Glutamate

    • Excitatory

    • Results in neurotoxicity if levels are too high

  • γ-Aminobutyric acid (GABA)

    • Inhibitory

    • Modulates other neurotransmitters

Psychoimmunology

  • a relatively new field of study, examines the effect of psychosocial stressors on the body’s immune system

  • compromised immune system could contribute to the development of a variety of illnesses, particularly in populations already genetically at risk

Psychopharmacology

  • use of medications to treat mental illness

  • medications directly affect the central nervous system (CNS) and subsequently behavior, perceptions, thinking, and emotions

Efficacy

  • refers to the maximal therapeutic effect that a drug can achieve.

Potency

  • describes the amount of the drug needed to achieve that maximum effect;

  • low-potency drugs require higher dosages to achieve efficacy

  • high-potency drugs achieve efficacy at lower dosages.

Half-life

  • is the time it takes for half of the drug to be removed from the bloodstream

  • shorter half-life may need to be given three or four times a day

  • drugs with a longer half-life may be given once a day

  • the time that a drug needs to leave the body completely after it has been

    discontinued is about five times its half-life

Off-label use

  • a drug will prove effective for a disease that differs from the one involved in original testing and FDA approval

Black Box Warning

  • a drug is found to have serious or life-threatening side effects, even if such side effects are rare

Principles that Guide Pharmacologic Treatment

  • selected based on its effect on the client’s target symptoms; effectiveness is evaluated largely by its ability to diminish or eliminate the target symptoms

  • drugs must be given in adequate dosages for some time before their full effects are realized

  • dosage of medication is often adjusted to the lowest effective dosage

    for the client

  • older adults require lower dosages of medications than do younger clients to experience therapeutic effects; take longer for a drug to achieve its full therapeutic effect

  • psychotropic medications are often decreased gradually (tapering) rather

    than abruptly; potential problems with:

    • rebound

      • temporary return of symptoms

    • recurrence of the original symptoms

    • withdrawal

      • new symptoms resulting from discontinuation of the drug

  • Follow-up care is essential to ensure:

    • compliance with the medication regimen

    • to make needed adjustments in dosage

    • to manage side effects

  • Compliance with the medication regimen is often enhanced when the

    regimen is as simple as possible in terms of both the number of medications prescribed and the number of daily doses


Antipsychotic Drugs

  • formerly known as neuroleptics

  • used to treat the symptoms of psychosis, such as:

    • delusions and hallucinations seen in schizophrenia

    • schizoaffective disorder

    • manic phase of bipolar disorder

  • Off-label:

    • treatment of anxiety and insomnia

    • aggressive behavio

    • delusions

    • hallucinations

    • other disruptive behaviors that sometimes accompany Alzheimer disease

  • primary medical treatment for schizophrenia and are also used in psychotic episodes of:

    • acute mania

    • psychotic depression

    • drug-induced psychosis

  • Second-generation antipsychotics can increase mortality rates in elderly clients with dementia-related psychosis

Mechanism of Action

  • work by blocking receptors of the neurotransmitter dopamine

  • Dopamine receptors: D2, D3, and D4 have been associated with mental illness

  • conventional, or first-generation, antipsychotic drugs are potent antagonists of these dopamine receptors

    • produces many extrapyramidal side effects because of the

      blocking of the D2 receptors

  • atypical or second-generation antipsychotic drugs: clozapine (Clozaril)

    • relatively weak blockers for D2 resceptors; this account for the lower incidence of extrapyramidal side effects

    • inhibit the reuptake of serotonin increasing their effectiveness in treating the depressive aspects of schizophrenia

    • Examples:

      • Paliperidone (Invega)

        • chemically similar to Risperidone (Risperdal)

        • it is an extended-release preparation; take one daily dose in most cases = increase compliance

      • Iloperidone (Fanapt)

      • Asenapine (Saphris)

        • a sublingual tablet

        • avoid food or drink for 10 to 15 minutes after the medication dissolves

      • Lurasidone (Latuda)

  • third generation of antipsychotics are called dopamine system stabilizers

    • thought to stabilize dopamine output

    • preserve or enhance dopaminergic transmission when it is too low and reduce it when it is too high

    • results in control of symptoms without some of the side effects of other antipsychotic medications

      • Aripiprazole (Abilify)

        • the first drug of this type, was approved for use in 2002.

      • Cariprazine (Vraylar) and Brexpiprazole (Rexulti)

        • newer third-generation

        • used for schizophrenia, manic episodes, and

          as adjunct medication in both bipolar disorder and depression

    • The most common side effects are:

      • sedation

      • weight gain

      • akathisia

      • headache

      • anxiety

      • nausea

  • Depot Injection

    • a time-release form of intramuscular medication for maintenance therapy

    • six (6) antipsychotics are available in this form, some of it are:

      • Risperidone (Risperdal Consta)

        • 25 mg, is given every 2 weeks

      • Paliperidone (Invega Sustenna)

        • 117 mg, is given every 4 weeks

      • Olanzapine pamoate (Zyprexa Relprevv)

        • given 210 mg every 2 weeks or 405 mg every 4 weeks

        • potential to cause postinjection delirium/sedation syndrome, characterized by:

          • sedation

          • confusion

          • disorientation

          • agitation, and

          • cognitive impairment, that can progress to:

            • ataxia

            • convulsions

            • weakness, and

            • hypertension, which can lead to arrest

        • client is monitored q3hrs post injection and must be:

          • alert

          • oriented

          • symptom-free

    • Two first-generation antipsychotics use sesame oil as the vehicle for these injections

      • medication is absorbed slowly over time

      • thus, less frequent administration is needed to maintain the desired therapeutic effects

      • examples:

        • Decanoate Fluphenazine (Prolixin)

          • duration of 7 to 28 days

        • Decanoate Haloperidol (Haldol)

          • duration of 4 weeks

          • After condition is stabilized with oral doses administration by depot injection is required every 2 to 4 weeks to maintain the therapeutic effect

    • it also includes third-generation antipsychotic:

      • Aripiprazole (Abilify Maintena)

        • slowly absorbed into the bloodstream because of

          insolubility of aripiprazole particles

Side Effects

  • Extrapyramidal symptoms (EPS) includes:

    • acute dystonia

      • characterized by:

        • acute muscular rigidity and cramping

        • a stiff or thick tongue with difficulty swallowing

        • in severe cases:

          • laryngospasm

          • respiratory difficulties

      • likely to occur in:

        • first week of treatment

        • <40 years

        • males

        • receiving high-potency drugs:

          • haloperidol

          • thiothixene

      • Spasms or stiffness in muscle groups can produce:

        • torticollis

          • twisted head and neck

        • opisthotonus

          • tightness in the entire body with the head back and an arched neck

        • oculogyric crisis

          • eyes rolled back in a locked position

      • can be freightening to client; reason for them not to take the medication

      • immediate treatment of anticholinergic drugs is needed, such as:

        • IM benztropine mesylate (Cogentin)

        • IM/IV diphenhydramine (Benadryl)

      • a regularly scheduled oral anticholinergic may allow the client to continue taking the antipsychotic drug with no further

        dystonia

        • benztropine

      • Recurrent dystonic reactions would necessitate a lower dosage or a change in the antipsychotic drug

    • pseudoparkinsonism or drug-induced parkinsonism

      • generic label of EPS

      • symptoms resemble those of Parkinson disease and includes:

        • a stiff, stooped posture

        • masklike facies

        • decreased arm swing

        • a shuffling, festinating gait (with small steps)

        • cogwheel rigidity (ratchet-like movements of joints)

        • drooling; tremor

        • bradycardia

        • coarse pill-rolling movements of the thumb and fingers while at rest

      • treated by:

        • changing to an antipsychotic medication that has a lower incidence of EPS

        • adding an oral anticholinergic agent or amantadine to increase transmission of dopamine

    • akathisia

      • an intense need to move about

      • may appear as:

        • restless or anxious and agitated

        • rigid posture or gait

        • lack of spontaneous gestures

      • reasosn for drug discontinuation:

        • feeling of internal restlessness

        • inability to sit still or rest

      • treated by:

        • change in antipsychotic medication

        • the addition of an oral agent such as:

          • beta-blocker

          • anticholinergic

          • benzodiazepine

    • therapies for these EPS include:

      • lowering the dosage of the antipsychotic

      • changing to a different antipsychotic

      • administering anticholinergic medication


WARNING!

  • Atypical Antipsychotics

    • Elderly patients with dementia-related psychosis are at an increased risk for death if treated with this mediaction.

    • cause of death may appear to be cardiovascular or infectious in nature

  • Geodon

    • Contraindicated in patients with a:

      • known history of QT prolongation

      • recent myocardial infarction

      • uncompensated heart failure

    • it should not be used with other QT-prolonging drugs


  • Neuroleptic Malignant Syndrome (NMS)

    • potentially fatal idiosyncratic reaction to an antipsychotic drug

    • major symptoms:

      • rigidity

      • high fever

      • autonomic instability such as:

        • unstable blood pressure

        • diaphoresis

        • pallor

      • delirium

      • elevated levels of enzymes

        • creatine phosphokinase

    • patient usually present as:

      • confused and often mute

      • may fluctuate from agitation to stupor

    • often occurs in the first 2 weeks of therapy or after an increase in dosage, but it can occur at any time

    • factors thtat increase the risk of NMS:

      • Dehydration

      • poor nutrition

      • concurrent medical illness

    • treatment:

      • immediate discontinuance of all antipsychotic medications

      • institution of supportive medical care to treat:

        • dehydration

        • hyperthermia

    • to treat the client with other antipsychotic drugs requires full discussion between the client and the physician to weigh the relative risks against the potential benefits of therapy.

  • Tardive dyskinesia (TD)

    • syndrome of permanent involuntary movements

    • most commonly caused by the long-term use of conventional antipsychotic drugs

    • pathophysiology is still unclear

    • symptoms include:

      • involuntary movements of the tongue, facial and

        neck muscles, upper and lower extremities, and truncal musculature

    • characterized by:

      • Tongue thrusting

      • protruding

      • lip smacking

      • blinking

      • grimacing

      • other excessive unnecessary facial movements

    • after its development, it becomes irreversible

      • decreasing or discontinuing antipsychotic medications can arrest its progression

    • antipsychotic medications can mask the beginning symptoms of TD

      • increased dosages of the antipsychotic medication cause the initial symptoms to disappear temporarily

      • as it worsen, they “break through” the effect of the antipsychotic drug

    • drug treatment includes:

      • Valbenazine (Ingrezza)

        • dosage range of 40 to 80 mg

        • cause:

          • nausea

          • vomiting

          • headache

          • balance disturbances

      • Deutetrabenazine (Austedo, Teva)

        • from 12 to 48 mg daily

        • may caus:

          • NMS

          • increased depression

          • increased suicidality with Huntington chorea

      • first drugs to treat TD

      • are vesicular monoamine transporter 2 (VMAT2) inhibitors

      • decrease activity of monoamines, such as dopamine, serotonin, and norepinephrine, thereby decreasing the abnormal movements associated with Huntington chorea and TD

      • effects of the drugs include:

        • somnolence

        • QT prolongation

        • akathisia

        • restlessness

    • goal for antipsychotics:

      • prevent TD through:

        • keeping maintenance dosages as low as possible

        • changing medications

        • monitoring the client periodically for initial signs of TD through:

          • standardized assessment tool - Abnormal Involuntary

            Movement Scale

  • Anticholinergic Side Effects

    • often occur with the use of antipsychotics and include:

      • orthostatic hypotension

      • dry mouth

        • can be alleviated through using of:

          • calorie-free beverages

          • hard candy

      • constipation

        • can be prevented through using of:

          • stool softeners

          • adequate fluid intake

          • inclusion of grains and fruit in the diet

      • urinary hesitance or retention

      • blurred near vision

      • dry eyes

      • photophobia

      • nasal congestion

      • decreased memory

    • side effects usually decrease within 3 to 4 weeks but do not entirely remit

    • client taking anticholinergic agents for EPSs may have increased problems with anticholinergic side effects

  • Other Side Effects

    • increase blood prolactin levels, and may cause:

      • breast enlargement and tenderness in men and

        women

      • diminished libido

      • erectile and orgasmic dysfunction

      • menstrual irregularities

      • increased risk for breast cancer

      • weight gain

        • mostly on 2nd generation, except:

          • Ziprasidone (Geodon)

        • significant on:

          • Clozapine (Clozaril)

          • Olanzapine (Zyprexa)

        • mechnism is unknown; is associated with:

          • increased appetite

          • binge eating

          • carbohydrate craving

          • food preference changes

          • decreased satiety in some clients

        • histamine antagonism stimulates appetite

        • genetics make client more prone to weight gain and metabolic syndrome:

          • cluster of conditions that increase the risk for:

            • heart disease

            • diabetes

            • stroke

          • The syndrome is diagnosed when three or more

            of the following are present:

            • Obesity

              • excess weight, increased body mass index (BMI), and increased 81 abdominal girth because of fat deposits

              • common in clients with schizophrenia, further increasing the risk for type 2 diabetes mellitus and cardiovascular disease

            • Increased blood pressure

            • High blood sugar level

            • High cholesterol

              • with at least 150 mg/dL of triglyceride; less than 40 mg/dL of high-density lipoprotein for women and 50 mg/dL for men

        • recommended that:

          • clients taking antipsychotics be involved in an

            educational program to control weight and decrease BMI

          • found that clients had greater success when staff provided information and practical support when it was needed

    • cardiovascular adverse effects

      • may include:

        • postural hypotension

        • palpitations

        • tachycardia

    • increase QT intervals

      • may be caused by drugs such as:

        • thioridazine (Mellaril)

        • droperidol (Inapsine)

        • mesoridazine (Serentil)

      • QT interval longer than 500 ms is considered dangerous and is associated with:

        • life-threatening dysrhythmias

        • sudden death

      • in rare cases, it can cause torsade de pointes

        • rapid heart rhythm of 150 to 250 beats/minute

        • present as “twisted” appearance on the electrocardiogram

      • other drugs:

        • Thioridazine and Mesoridazine

          • used to treat psychosis

        • Droperidol

          • most often used as an adjunct to anesthesia or to produce sedation.

        • Sertindole (Serlect)

          • never approved in the US to treat psychosis

          • used in Europe and was subsequently withdrawn from the market because of the number of cardiac dysrhythmias and deaths that it caused


WARNING!

  • Droperidol, Thioridazine, and Mesoridazine

    • lengthen the QT interval, leading to potentially life-threatening cardiac dysrhythmias or cardiac arrest

  • Clozapine

    • cause agranulocytosis

      • potentially life-threatening event

      • characterized by:

        • fever

        • malaise

        • ulcerative sore throat

        • leukopenia

      • may not manifest immediately

      • occur up to 24 weeks after the initiation of therapy

    • clients must have:

      • baseline WBC count (> 3,500/mm3) and differential before initiation of treatment

      • WBC count every week throughout treatment and for 4 weeks after discontinuation of clozapine

      • neutrophil count (ANC) is 2,000/mm3


Client Teaching

  • Nurse informs clients taking antipsychotic medication about the types of

    side effects that may occur

    • encourages clients to report such problems to the physician instead of discontinuing the medication

  • Nurse teaches the client methods of managing or avoiding unpleasant side effects and maintaining the medication regimen

  • Drinking sugar-free fluids and eating sugar-free hard candy ease dry mouth

  • The client should avoid calorie-laden beverages and candy

    • promote dental caries, contribute to weight gain, and do little to relieve dry mouth

  • Methods to prevent or relieve constipation include:

    • exercising and increasing water and bulk-forming foods in the diet

    • Stool softeners are permissible, but the client should avoid laxatives

  • Use of sunscreen is recommended because photosensitivity can

    cause the client to sunburn easily

  • Clients should monitor the amount of sleepiness or drowsiness they feel

  • Should avoid driving and performing other potentially dangerous

    activities until their response times and reflexes seem normal

  • If the client forgets a dose of antipsychotic medication, he or she can take the missed dose if it is only 3 or 4 hours late

    • dose is more than 4 hours overdue or the next dose is due, the client can omit the forgotten dose

    • nurse encourages clients who have difficulty remembering to take their medication to use:

      • chart and to record doses when taken

      • pillbox that can be prefilled with accurate doses for the day or week


Antidepressant Drugs

  • primarily used in the treatment of:

    • major depressive illness

    • anxiety disorders

    • the depressed phase of bipolar disorder

    • psychotic depression

  • Off-label:

    • chronic pain

    • migraine headaches

    • peripheral and diabetic neuropathies

    • sleep apnea

    • dermatologic disorders

    • panic disorder

    • eating disorders

  • mechanism of action is not completely understood; interact with the two neurotransmitters:

    • norepinephrine and serotonin

      • regulating mood, arousal, attention, sensory processing, and appetite

  • divided into 4 groups:

    • Tricyclic and the related cyclic antidepressants

      • available in the 1950s

      • first choice of drugs to treat depression; even it cause varying

        degrees of:

        • sedation

        • orthostatic hypotension

        • anticholinergic side effects

      • potentially lethal if taken in an overdose

    • Selective serotonin reuptake inhibitors (SSRIs)

      • first available in 1987

      • release of fluoxetine (Prozac)

        • Prozac Weekly

          • first and only medication that can be given once a week

          • for maintenance therapy for depression

          • It contains 90 mg of fluoxetine with an enteric coating that delays release into the bloodstream

      • replaced the cyclic drugs as the first choice in treating depression

        • equal in efficacy and produce fewer troublesome side effects

      • SSRIs and clomipramine are effective in the treatment of obsessive-compulsive disorder (OCD)

    • MAO inhibitors (MAOIs)

      • discovered to have a positive effect on people with depression

      • low incidence of sedation and anticholinergic effects; must be used with extreme caution:

        • hypertensive crisis occurs with ingestion of foods containing tyramine

        • MAOIs cannot be given in combination with other MAOIs, tricyclic antidepressants, meperidine (Demerol), CNS depressants, many antihypertensives, or general anesthetics

        • potentially lethal in overdose and pose a potential risk in clients

          with depression who may be considering suicide

    • Other antidepressants:

      • desvenlafaxine (Pristiq)

      • venlafaxine (Effexor)

      • bupropion (Wellbutrin)

      • duloxetine (Cymbalta)

      • trazodone (Desyrel)

      • nefazodone (Serzone)

Preferred Drugs for Clients at High Risk for Suicide

  • SSRIs, venlafaxine, nefazodone, and bupropion are often better

    choices

    • carry no risk of lethal overdose

  • SSRIs are effective only for mild and moderate depression

  • Evaluation of the risk for suicide must continue even after treatment with antidepressants is initiated

  • May feel more energized but still have suicidal thoughts

    • which increases the likelihood of a suicide attempt

  • Often takes weeks before the medications have a full therapeutic effect

    • clients may become discouraged and tired of waiting to feel better

      • can result in suicidal behavior

Mechanism of Action

  • precise mechanism is not known, but much is known about their action on the CNS

  • major interaction is with the monoamine neurotransmitter systems in the

    brain, particularly norepinephrine and serotonin

    • released throughout the brain and help regulate arousal, vigilance, attention, mood, sensory processing, and appetite

  • Norepinephrine, serotonin, and dopamine are removed from the synapses after release by reuptake into presynaptic neurons

    • reloaded for subsequent release or metabolized by the enzyme MAO

  • Cyclic compounds may take 4 to 6 weeks to be effective

  • MAOIs need 2 to 4 weeks for effectiveness

  • SSRIs may be effective in 2 to 3 weeks

Side Effects of Selective Serotonin Reuptake Inhibitors

  • have fewer side effects compared to the cyclic compounds

  • enhanced serotonin transmission can lead to several common side effects such as:

    • anxiety

    • agitation

    • akathisia

      • treated with a beta-blocker, such as:

        • propranolol (Inderal)

        • benzodiazepine

    • nausea

      • can be minimized through taking medications with food usually

    • insomnia

      • may continue to be a problem even if the client takes the medication in the morning

      • sedative–hypnotic or low-dosage trazodone may be needed

    • sexual dysfunction

      • diminished sexual drive

      • difficulty achieving an erection or orgasm

    • SSRIs cause less weight gain than other antidepressants

  • Less common side effects include:

    • sedation

      • particularly with paroxetine (Paxil)

      • indicate the need for a change to another antidepressant

    • sweating

      • indicate the need for a change to another antidepressant

    • hand tremor

    • diarrhea

      • managed with symptomatic treatment

    • headaches

      • usually be managed with symptomatic treatment

Side Effects of Cyclic Antidepressants

  • Cyclic compounds have more side effects

  • individual medications in this category vary in terms of the intensity of side effects

  • cyclic antidepressants block cholinergic receptors, resulting in anticholinergic effects such as:

    • dry mouth

    • constipation

    • urinary hesitancy or retention

    • dry nasal passages

    • blurred near vision

  • more severe anticholinergic effects such as:

    • agitation

    • delirium

    • ileus

      • particularly in older adults

  • Other common side effects include:

    • orthostatic hypotension

    • sedation

    • weight gain

    • tachycardia

  • Clients may develop tolerance to anticholinergic effects, but these side effects are common reasons that clients discontinue drug therapy

  • Clients taking cyclic compounds frequently report:

    • sexual dysfunction similar to problems experienced with SSRIs

    • weight gain too

Side Effects of Monoamine Oxidase Inhibitors

  • most common side effects:

    • daytime sedation

      • difficult to treat

      • necessitate a change in medication

    • insomnia

      • difficult to treat

      • necessitate a change in medication

    • weight gain

    • dry mouth

    • orthostatic hypotension

    • sexual dysfunction

  • potential for a life-threatening hypertensive crisis if the client s takes sympathomimetic drug or ingests food that contain tyramine:

    • Mature or aged cheeses or dishes made with cheese

    • Aged meats

    • Italian broad beans (fava), bean curd (tofu), banana peel, overripe fruit, and avocado

    • All tap beers and microbrewery beer

    • Sauerkraut, soy sauce or soybean condiments, or marmite

    • Yogurt, sour cream, peanuts, brewer’s yeast, and monosodium glutamate (MSG)

    • increased serum tyramine levels may cause:

      • severe hypertension

      • hyperpyrexia

      • tachycardia

      • diaphoresis

      • tremulousness

      • cardiac dysrhythmias

  • Drugs that may cause potentially fatal interactions:

    • SSRIs

    • certain cyclic compounds

    • buspirone (BuSpar)

    • dextromethorphan

    • opiate derivatives:

      • meperidine

Side Effects of Other Antidepressants

  • nefazodone

    • sedation

    • headaches

    • cause dry mouth

    • nausea

  • trazodone

    • sedation

    • headaches

    • cause priapism

      • a sustained and painful erection that necessitates immediate treatment and discontinuation of the drug

      • may also result in impotence

  • mirtazapine

    • sedation

  • bupropion and desvenlafaxine

    • cause loss of:

      • appetite

      • nausea

      • agitation

      • insomnia

  • Venlafaxine

    • may cause:

      • dizziness

      • sweating

      • sedation

      • plus the aforementioned cause of loss

Drug Interactions

  • Serotonin Syndrome (Serotonergic Syndrome)

    • uncommon but potentially serious drug interaction

    • result from taking an MAOI and an SSRI at the same time

    • also occur if the client takes one of these drugs too close to the end of therapy with the other

    • NOTE: one drug must clear the person’s system before initiation of therapy with the other

    • Symptoms include:

      • agitation

      • sweating

      • fever

      • tachycardia

      • hypotension

      • rigidity

      • hyperreflexia

      • extreme reactions:

        • coma

        • death

Client Teaching

  • take SSRIs first thing in the morning unless sedation is a problem

    • paroxetine most often causes sedation

  • if client forgets a dose of an SSRI, he or she can take it up to 8 hours after the missed dose

    • should take it within 3 hours of the missed dose or omit the dose for that day

  • to minimize side effects, clients generally should take cyclic compounds at night in a single daily dose when possible

  • exercise caution when driving or performing activities requiring sharp, alert reflexes until sedative effects can be determined

  • clients taking MAOIs need to be aware that a life-threatening hyperadrenergic crisis can occur if they do not observe certain dietary restrictions

    • should receive a written list of foods to avoid while taking MAOIs

  • The nurse should make clients aware of the risk for serious or even fatal drug interactions when taking MAOIs and instruct them:

    • not to take any additional medication, including OTC preparations, without checking with the physician or pharmacist


WARNING!

  • Nefazodone

    • cause rare but potentially life-threatening liver damage, which could lead

      to liver failure

  • Bupropion

    • may cause seizures at a rate four times that of other antidepressants

    • risk for seizures increases when:

      • doses exceed 450 mg/day (400 mg SR)

      • increases are sudden or in large increments

      • has a history of seizures, cranial trauma, excessive use of or withdrawal from alcohol, or addiction to opiates, cocaine, or stimulants

      • uses over-the-counter (OTC) stimulants or anorectics

      • has diabetes being treated with oral hypoglycemics or insulin


Mood-Stabilizing Drugs